Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Plos Pathogens|October 5, 2023
Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infectionMatilda J Moström, Shan Yu, Dollnovan Tran, et al.Breast Cancer Research and Treatment|October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapySara A Hurvitz, Florence Dalenc, Mario Campone, et al.NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.Biorxiv : the Preprint Server for Biology|May 7, 2026
Tectonic setting shapes microbial biosynthetic potential across global geothermal environmentsAna Clara Pelliciari Silva, Benoit de Pins, Francesco Montemagno, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneLinda T Vahdat, Brian Pruitt, Carol J Fabian, et al.JAMA Oncology|August 2, 2019
Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac Garcia-Murillas, Neha Chopra, Iñaki Comino-Méndez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast CancerPeter Barry, Alexandra Vatsiou, Inmaculada Spiteri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.Pageof 10